Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIC Haplo-HCT for Hematologic Malignancies
NCT04191187Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Dec 2019
- Primary completion
- Feb 2024
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label trial of fludarabine and melphalan in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and 4 more, sponsored by Moffitt Cancer Center. Primary endpoint: Disease-Free Survival at 18 months. Started Dec 2019; status: completed.
02
Drugs
fludarabinemelphalan
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)chronic myelogenous leukemia (CML)Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT04191187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04191187.